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Context: Mutations in the gene encoding Mediator complex subunit MED12 are dominant 50 
drivers of uterine fibroids (UFs) in women of diverse racial and ethnic origins. Previously, we 51 
showed that UF-linked mutations in MED12 disrupt its ability to activate Cyclin C-CDK8/19 in 52 
Mediator. However, validation of Mediator kinase disruption in the clinically relevant setting 53 
of MED12-mutant UFs is currently lacking.  54 
 55 
Objective: The objective of this study was two-fold. First, to extend the ethnic distribution 56 
profile of MED12 mutations by establishing their frequency in UFs from Hispanic women of 57 
South Texas. Second, to examine the impact of MED12 mutations on Mediator kinase activity 58 
in patient-derived UFs.  59 
 60 
Methods: We screened 219 UFs from 76 women, including 170 tumors from 57 Hispanic 61 
patients, for MED12 exon 2 mutations, and further examined CDK8/19 activity in Mediator 62 
complexes immunoprecipitated from MED12 mutation-negative and MED12 mutation-positive 63 
UFs.  64 
 65 
Results: MED12 exon 2 mutations in UFs from Hispanic women are somatic in nature, 66 
predominantly monoallelic, and occur at high frequency (54.1%). We identified a minimal 67 
Cyclin C-CDK8 activation domain on MED12 spanning amino acids 15-80 that includes all 68 
recorded UF-linked mutations in MED12, suggesting that disruption of Mediator kinase activity 69 
is a principal biochemical defect arising from these pathogenic alterations. Analysis of 70 
Mediator complexes recovered from patient UFs confirmed this, revealing that Mediator 71 
kinase activity is selectively impaired in MED12-mutant UFs.  72 
 3 
Conclusions: MED12 mutations are important drivers of UF formation in Hispanic women of 73 
South Texas. MED12 mutations disrupt Mediator kinase activity, implicating altered CDK8/19 74 
function in UF pathogenesis. 75 
 76 
 77 
  78 
 4 
Precis 79 
 80 
MED12 exon 2 mutations were found at high frequency (54.1%) in UFs from Hispanic 81 
women of South Texas, leading to selective disruption of Mediator kinase activity in 82 
MED12 mutation positive tumors.   83 
  84 
 5 
Introduction 85 
Uterine leiomyomas (uterine fibroids; UFs) are benign monoclonal neoplasms of the 86 
myometrium (MM) and represent the most common gynecological tumors in women 87 
worldwide (1,2). Tumors are estimated to occur in ~77% of women overall and are 88 
clinically manifest in ~25% by age 45 (1,2). Although benign, these tumors are 89 
nonetheless associated with significant morbidity; they are the primary indication for 90 
hysterectomy, and a major source of gynecologic and reproductive dysfunction, ranging 91 
from profuse menstrual bleeding and pelvic pain to infertility, recurrent miscarriage, and 92 
pre-term labor (1,2). Accordingly, the US annual health care costs associated with UFs 93 
have been estimated at ~$34 billion (3). Uterine fibroids thus represent a significant 94 
public health and financial burden. 95 
 Current treatment options for UFs are primarily surgical or radiological and range 96 
from hysterectomy or myomectomy to minimally invasive options, including uterine 97 
artery embolization (UAE) and magnetic resonance-guided focused ultrasound (MRgFUS) 98 
(4). However, the deleterious impact of these procedures on reproductive function is 99 
either clear (hysterectomy) or controversial (UAE, MRgFUS), rendering such options 100 
unsuitable for women who wish to retain future fertility (5). Likewise, hormonal 101 
therapies designed to blunt the stimulatory effects of estrogen or progesterone on fibroid 102 
growth are currently contraindicated in women actively pursuing a pregnancy, and are 103 
otherwise approved only for short-term use due to long-term safety concerns (6,7). 104 
Accordingly, no long-term noninvasive treatment option currently exists for UFs, and 105 
deeper mechanistic insight concerning tumor etiology will be key to develop newer 106 
targeted therapies. 107 
 In this regard, the prevailing model for UF pathogenesis invokes the genetic 108 
transformation of a single MM stem cell (MM SC) into a tumor-initiating cell (UF SC) that 109 
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seeds and sustains clonal tumor growth, characterized by an increase in cell size and 110 
number, as well as abundant extracellular matrix production, under the influence of 111 
endocrine, autocrine, and paracrine growth factor and hormone receptor signaling (8-10). 112 
Recent advanced genomic technologies, including high-throughput sequencing 113 
methodologies, have identified recurrent and mutually exclusive genetic alterations (i.e., 114 
drivers) thought dominantly responsible for cell transformation. Among these, somatic 115 
mutations in the Xq13 gene encoding the RNA polymerase II (Pol II) transcriptional 116 
Mediator subunit MED12 are by far the most prevalent, occurring in 45-80% of UFs in 117 
various studies (11,12). Notably, MED12 is recurrently mutated at high frequency in UFs 118 
from women of diverse racial and ethnic origins, including those of North American, 119 
European, African, Asian, and Middle Eastern descent, implicating MED12 as a dominant 120 
universal driver of UFs (13-22). A proportionally smaller fraction of tumors are thought to 121 
arise from genetic alterations leading to overexpression of HMGA2 (~20%), disruption of 122 
COL4A5-COL4A6 locus (~3%), biallelic loss of fumarate hydratase (FH; ~2%), or unknown 123 
molecular genetic processes  (12,23). Additionally, recurrent deletions and rearrangements 124 
involving chromosomes 6p21, 7q22, 22q, and 1p have been observed in UFs; however, these 125 
lesions generally co-occur with other genetic alterations, suggesting that they may represent 126 
secondary driver events restricted to a subpopulation of tumor cells (17,24-26). Altogether, 127 
the identification of different prospective driver mutations in UFs suggests the existence of 128 
distinct molecular subtypes with possibly unique pathways to tumorigenesis.   129 
The revelation that MED12 is recurrently mutated at high frequency in UFs implicates 130 
dysregulation of RNA polymerase II (Pol II)-dependent gene expression in fibrotic 131 
transformation. Mediator is a conserved multiprotein interface between gene-specific 132 
transcription factors and Pol II (27). In this capacity, Mediator channels regulatory signals 133 
from activator and repressor proteins to affect changes in gene expression programs that 134 
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control diverse physiological processes, including cell growth and homeostasis, development, 135 
and differentiation. Structurally, Mediator is assembled from a set of 26 core subunits into 136 
three distinct modules termed “head”, “middle”, and “tail” that bind tightly to Pol II in the 137 
so-called holo-enzyme (27). MED12, MED13, CycC, and CDK8 (or its paralog CDK19) comprise a 138 
four-subunit “kinase” module that variably associates with core Mediator (27). The kinase 139 
module has been implicated in activation as well as repression of transcription through 140 
mechanisms both dependent and independent of its resident CDK8/CDK19 kinase activity. 141 
Mediator kinase-dependent gene regulation has been attributed to CDK8/19-targeted 142 
phosphorylation events that impact transcription factor half-life, Pol II activity, and 143 
chromatin chemistry and functional status (27,28). Notably, the kinase module is a major 144 
ingress of signal transduction through Mediator, and MED12-dependent CDK8 activation is 145 
required for nuclear transduction of signals instigated by multiple oncogenic pathways 146 
with which MED12 is biochemically and genetically linked (27). Furthermore, MED12 is a 147 
target of oncogenic mutation in colon, prostate, and renal cell carcinomas (29-31). However, 148 
these mutations occur predominantly in the MED12 C-terminus and thus lie distant from UF-149 
linked mutations that cluster in its N-terminus, suggesting possible distinct etiological 150 
mechanisms (32).  151 
Regarding UF-linked mutations in MED12, all lesions heretofore recorded impact 152 
exons 1 and 2 and most are missense, with a smaller proportion corresponding to in 153 
frame deletions and insertions (16,23,27). UF-linked MED12 exon 2 mutations are far 154 
more frequent than those occurring in exon 1, with latter accounting for ~6% of 155 
pathogenic alterations reported in uterine fibroids (23). Although missense mutations in 156 
exon 2 are distributed throughout the coding sequence, most are clustered in codons 36, 157 
43, and 44, suggesting an important function for their corresponding and highly conserved 158 
amino acid residues. Along with their high frequency occurrence, two additional genetic 159 
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findings suggest that MED12 mutations are drivers of fibrotic transformation. First, 160 
predominant monoallelic expression of mutant MED12 has been observed in UF tumors, 161 
indicative of a pathogenic requirement for a functionally altered MED12 allele 162 
(16,23,27). Second, directed expression of a MED12 mutant transgene (c. 131G>A; 163 
p.G44D) in the uterine compartment of mice is sufficient to induce UF formation, 164 
providing direct genetic proof of disease causality (33). Nonetheless, the impact of UF-165 
linked mutations on MED12 function and the molecular basis for their tumorigenic 166 
potential remain to be clarified.  167 
In this regard, we previously reported that UF-linked exon 1 and 2 mutations in 168 
MED12 lead to disruption of Mediator-associated CDK activity, with significant 169 
implications for global dysregulation of gene expression programs. Mechanistically, we 170 
showed that these UF-linked mutations in MED12 disrupt its ability to bind directly to 171 
CycC, an interaction necessary for MED12-mediated activation of CycC-dependent 172 
CDK8/19 within Mediator (23,34,35). These findings identified for the first time a common 173 
molecular defect associated with UF-linked mutations in MED12 and further implicate 174 
aberrant CDK8/19 activity in UF pathogenesis. Nonetheless, direct validation of Mediator 175 
kinase disruption in the clinically relevant setting of MED12-mutant uterine fibroid 176 
tumors has only very recently been reported from a restricted set of Caucasian (Finnish 177 
patients) (34). Therefore, the objective of this study was two-fold; first, to establish the 178 
frequency of MED12 mutations in UFs from Hispanic women of south Texas in an effort to 179 
further catalog MED12 driver alterations in diverse ethnic populations, and second, to 180 
examine the impact of tumorigenic MED12 mutations on Mediator kinase activity in 181 
clinically relevant patient fibroids. To this end, we screened a total of 219 fibroid tumors 182 
from 76 women, including a large subset from Hispanic patients, for MED12 exon 2 183 
mutations, and further examined kinase activity within Mediator complexes recovered 184 
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from MED12 mutation-negative and MED12 mutation-positive UFs as well as adjacent 185 
normal myometrium. We found that MED12 exon 2 mutations occur at high frequency 186 
(54.1%) in Hispanic patients, suggesting that MED12 mutations are important drivers of UF 187 
formation in this ethnic population. Moreover, we document that Mediator kinase activity 188 
is indeed selectively and severely impaired in MED12-mutant UFs. Together, these findings 189 
confirm in a clinically relevant setting that UF-linked mutations in MED12 disrupt Mediator-190 
associated CDK activity and provide additional evidence to implicate altered CDK8/19 activity 191 
in the pathogenesis of MED12-mutant uterine fibroids.  192 
 193 
Materials and Methods 194 
Patient Samples  195 
This study was approved by the Institutional Review Board of the University of Texas 196 
Health Science Center at San Antonio. Uterine fibroid and myometrium samples were 197 
collected as fresh frozen tissues from informed consent patients undergoing hysterectomy. 198 
Sample histology was reviewed by a board certified gynecologic pathologist. In total, 219 199 
uterine fibroid and 28 myometrium samples from 76 patients, including 57 Hispanic women, 9 200 
African American women, 8 Caucasian women, 1 Iranian woman, and 1 Chinese woman were 201 
analyzed. Patient age ranged from 28-61 years with a mean of 42.4 years. 202 
 203 
Mutation Analysis  204 
Genomic DNA from UF tumors and corresponding myometrial samples was extracted from 100 205 
mg of fresh tissues using tissue lysis buffer (10mM Tris pH 7.5, 10mM EDTA pH 8.0, 10mM NaCl, 206 
0.5% sodium sarcosyl) with proteinase K followed by ethanol precipitation. MED12 exon 2 207 
mutations were screened by polymerase chain reaction (PCR) direct sequencing. The primer 208 
sequences in the 5’ to 3’ direction were AAGTGAACGTAAGGGCCCAG (forward) and 209 
 10 
AATGGCACTCTGGGATCGTG (reverse). The PCR products were purified with Gel Extraction Kit 210 
(QIAGEN, Valencia, CA, USA) prior to Sanger sequencing (GENEWIZ, South Plainfield, NJ, USA). 211 
The sequences were analyzed manually for the MED12 gene exon 2 somatic mutations.   212 
 213 
RNA extraction and RT-PCR 214 
Tissue samples (100 mg) were treated with TRI Reagent (Life Technologies) as 215 
recommended by the manufacturer and RNA was extracted using Direct-zol RNA mini prep kit 216 
(Zymo Research).  The RNA concentration and purity were determined by spectrophotometry. 217 
1ug of RNA was converted to cDNA using ImProm-II Reverse Transcription System (Promega) 218 
according to the manufacturer’s instructions.  219 
 220 
cDNA sequencing 221 
MED12 exon 2 cDNAs from uterine fibroid tissues were sequenced to verify that the 222 
mutated allele was actively expressed in each tumor. The primer sequences in the 5’ to 3’ 223 
direction are GGCTTCCCTCGGTAGTTTCC (forward) and TGCTGCATAGTAGGCACAGG (reverse) 224 
covering all the observed mutations. PCR products were gel purified using the QIAGEN PCR 225 
purification Kit (QIAGEN, Valencia, CA, USA) prior to Sanger sequencing (GENEWIZ, South 226 
Plainfield, NJ, USA).     227 
 228 
Glutathione S-Transferase (GST) Pull-down and Kinase assays 229 
GST-MED12 derivatives, including GST-MED12 (1-100) and its N-terminal (10-100, 15-100, 230 
20-100) and C-terminal (1-60, 1-72, 1-80) truncation forms were purified from E.coli lysates 231 
using Glutathione Sepharose 4B for 1 hour at 4oC. Beads were washed 4 times with Lysis250 232 
(50mM Tris pH 7.5, 250mM NaCl, 5mM EDTA) and insect cell lysates containing baculovirus-233 
expressed recombinant human CycCH6-CDK8-FLAG proteins were incubated with immobilized 234 
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GST-MED12 derivatives for 1 hour at 4oC. Complexes were washed 4 times in Lysis250 and 235 
either eluted in Laemmli sample buffer and resolved by SDS-10%-PAGE for western blot 236 
analysis, or incubated with kinase reaction buffer (25 mM Tris pH 7.5, 20 mM MgCl2), 2.5 mCi 237 
[g-32P] ATP and 2 ug of purified GST or GST-3xCTD substrate bearing 3 tandem copies of a 238 
consensus heptapeptide sequence from the RNA Pol II large subunit carboxyl-terminal domain. 239 
Kinase reactions were incubated for 30 minutes at 30oC, eluted in Laemmli sample buffer, 240 
processed by SDS-12% PAGE, and stained with Coomassie stain and visualized by 241 
phosphorimager analysis. 32P-labeled GST-CTD was quantified using ImageQuant software.  242 
 243 
Immunoprecipitation from human tissue samples 244 
Fresh frozen myometrium and uterine fibroid tissues were homogenized at 4 o C in protein 245 
lysis buffer (40mM Tris pH 7.4, 500mM NaCl, 0.5% Sodium-deoxycholic acid, 1% Triton X-100, 246 
and 1mM EDTA). Tissue homogenates were pre-cleared by incubation with protein A-agarose. 247 
Pre-cleared lysates were then incubated with anti-MED12 antibody covalently to protein A-248 
agarose (Millipore Corp). As a negative control, tissue lysates were incubated with normal 249 
rabbit IgG-agarose conjugate (Santa Cruz Biotechnology, Inc). Immunoprecipitations were 250 
performed for 3 hour at 4 o C. The beads were washed three times with 400 ul of wash buffer 251 
(40mM Tris pH 7.4, 500mM NaCl, 1mM EDTA). Immunoprecipitaes were either eluted in 252 
Laemmli sample buffer and either processed by SDS-10% PAGE for western blot analysis, or 253 
incubated with kinase reaction buffer (25 mM Tris pH 7.5, 20 mM MgCl2), 2.5 mCi [g-32P] ATP 254 
and 2 ug of purified GST or GST-3xCTD. 32P-labeled GST-3xCTD was resolved by SDS-12% PAGE, 255 
stained with Coomassie stain and visualized by Phosphoimager analysis. The 32P-labeled GST-256 
3xCTD was quantitated using ImageQuant software, and levels of phosphorylation from 257 
MED12-mutant immunoprecipates were relatively compared to those from MED12 WT 258 
immunoprecipitates.  259 
260 
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Results 261 
 262 
MED12 is frequently mutated in UFs from Hispanic women of South Texas 263 
 264 
In total, we sequenced 219 UFs from 76 patients, including 170 tumors from 57 Hispanic 265 
women, for evidence of MED12 exon 2 mutations (Tables 1 and 2; Supplementary Tables 266 
S1-S4). In addition, matched myometrial tissues available from 28 patients were also 267 
included for sequence analysis (Tables S3 and S4). Among sequenced UFs, 121 of 219 268 
tumors total (55.3%), including 92 of 170 (54.1%) from Hispanic patients, harbored a 269 
mutation in MED12 exon 2 (Fig. 1 and Table 2; Fig. S1 and Tables S3 and S4). Notably, the 270 
vast majority of these MED12 mutations [104 of 121 total (85.9%); 79 of 92 from Hispanic 271 
patients (85.8%)] corresponded to missense mutations in codon 44 (Table 3). In addition, 272 
among the 121 total MED12-mutant UFs, 10 carried a missense mutation in codon 36, 1 273 
carried a missense mutation in codon 68, and 6 carried in-frame exonic deletions that 274 
variously spanned 3-13 codons in length (Table 3). Among the 92 UFs from Hispanic 275 
patients, 8 harbored codon 36 mutations and 4 displayed in-frame exonic deletions. As 276 
expected, no mutations were found in adjacent myometrium, confirming the somatic 277 
nature of the UF mutations in MED12 (Fig. 1; Fig. S1; Tables S3 and S4). All tumors 278 
examined carried only one MED12 mutation, and all mutations were heterozygous in 279 
nature, with the mutant allele predominantly expressed. Thus, cDNA sequencing revealed 280 
that tumors harboring missense mutations and deletions internal to exon 2 expressed 281 
both mutated and wild-type alleles, with the former generally more abundant than the 282 
latter (Fig. 1). Consistent with prior published findings, a significant correlation was 283 
observed between MED12 mutation status and fibroid tumor size, with tumors carrying 284 
the most frequent MED12 mutation (c.131G>A; p.G44D; 40/121 or 33% of total UFs) found 285 
to be statistically significantly smaller than those without MED12 mutations (P < 0.01). 286 
Interestingly, however, this relationship was lost when all MED12 mutations were 287 
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considered, a distinction not observed in previous studies. Beyond tumor size, no 288 
correlations were observed between MED12 mutation status and either UF number or 289 
location, nor were any relationships noted between MED12 mutation status and patient 290 
age, BMI, or parity.  291 
 292 
Identification of a minimal CycC-CDK8/19 binding and activation domain on MED12 293 
 Previously, we and others have shown that MED12 is an obligate activator of CycC-294 
CDK8/19 in Mediator (34,35). Mechanistically, we showed that MED12 allosterically 295 
activates both CDK8 and CDK19 through a direct interaction between MED12 and a 296 
phylogenetically conserved surface groove on CycC (34,35). Importantly, we mapped the 297 
CycC-binding interface on MED12 to its N-terminal 100 amino acids [MED12 (1-100)] and 298 
further showed that UF-linked exon 1 and 2 mutations, all of which lie within MED12 (1-299 
100), disrupt the ability of MED12 to bind CycC and thus activate CDK8/19 (34,35). To 300 
further delineate the CycC-binding (and thus CDK8/19 activation) domain on MED12, we 301 
used purified recombinant GST-MED12 (1-100) to generate a derivative series of N- and C-302 
terminal MED12 truncation mutants (Fig. 2A), each of which was tested for its respective 303 
ability to bind and activate recombinant baculovirus-expressed CycC-CDK8. As expected 304 
GST-MED12 (1-100) exhibited robust CycC-CDK8 binding and activation function (Fig. 2B 305 
and C). Stepwise truncation of C-terminal residues from MED12 (1-100) revealed that 306 
deletion of more than 20 amino acids significantly impaired its ability to bind and 307 
activate CycC-CDK8. Thus, whereas GST-MED12 (1-80) bound and activated CycC-CDK8 308 
comparably to GST-MED12 (1-00), GST-MED12 (1-72) exhibited little activity (Fig. 2B). In 309 
contrast to the stark reduction in CycC-CDK8 binding and stimulatory activity observed 310 
upon stepwise truncation of C-terminal residues, serial truncations from the N-terminus 311 
of MED12 (1-100) led instead to a gradual loss of function, eventually resulting in 312 
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significantly impaired CycC-CDK8 binding and stimulatory activity following deletion of 313 
the first 15 amino acids of MED12. Thus whereas GST-MED12 (15-100) retained ~80% of 314 
the CycC-CDK8 binding and stimulatory activity of GST-MED12 (1-100), GST-MED12 (20-315 
100) exhibited only ~30% of such activity (Fig. 2C). Together, these analyses delimit the 316 
CycC-CDK8 binding and activation domain on MED12 to amino acids 15-80 that completely 317 
circumscribe the region on MED12 (amino acids 26-68) affected by UF-linked MED12 318 
mutations (Fig. 2D).  319 
 320 
Mediator kinase activity is selectively disrupted in MED12 mutation-positive UFs 321 
The observation that all UF-linked mutations in MED12 occur exclusively within its 322 
CycC-CDK8 binding and activation domain lends strong support for the notion that 323 
disruption of Mediator kinase activity is a primary molecular defect arising from these 324 
oncogenic alterations in MED12. In fact, our prior discovery that UF-linked exon 1 and 2 325 
mutations in MED12 disrupt its CycC-CDK8/19 binding and activation functions directly 326 
supports this hypothesis (23,35). However, these prior findings arose from biochemical 327 
and cell biological studies using purified recombinant proteins or ectopically expressed 328 
MED12 WT and mutant derivatives in non-uterine cells. More recently, we validated these 329 
findings in the clinically relevant setting of MED12 mutation positive UFs; however, these 330 
observations derived from analysis of UF tumors from a relatively restricted set of 331 
Caucasian (Finnish) patients (34). Therefore, to examine the functional impact of MED12 332 
mutations in UFs from a more diverse (Hispanic) patient pool, we comparatively assessed 333 
MED12-specific immunoprecipitates from MED12 WT and mutant UFs for CDK8/19 kinase 334 
activity. For these experiments, UF samples from patients harboring MED12 WT or MED12 335 
mutant (G44R, G44D, G44V) tumors were used for comparative analyses. Notably, all of the 336 
mutant MED12 proteins were expressed and co-precipitated Mediator subunits comparably to 337 
 15 
WT MED12, indicating that UF-linked mutations in MED12 do not aberrantly affect its stable 338 
expression or incorporation into Mediator (Fig. 3A-C, top panels). Importantly, as predicted 339 
from our prior studies, CDK8/19 kinase activity was significantly impaired in mutant 340 
MED12/Mediator complexes compared to their WT counterparts (Fig 3A-C, bottom panels). 341 
These findings confirm that Mediator kinase activity is selectively disrupted in MED12-mutant 342 
uterine fibroid tumors.  343 
 344 
Discussion 345 
Herein, we show that MED12 is recurrently mutated at high frequency (54.1%) in UFs from 346 
Hispanic women, leading to disruption of Mediator-associated kinase activity. This MED12 347 
mutation frequency is similar to reported frequencies in women of Korean (52.2%), 348 
Chinese (46.2%), Iranian (34.1%), and South African (50%) ancestry, but lower than that 349 
reported in Finnish (Caucasian) and North American (African American and Caucasian) 350 
women, where MED12 mutation frequencies range from 60-85% in various studies (13-22). 351 
Whether these observed differences in the MED12 mutation frequency reflect study bias 352 
(e.g., whole exome versus targeted sequencing, size of fibroids selected for analysis, 353 
etc.) or bona fide racial and ethnic disparity will require further analyses with expanded 354 
data sets. We note that the MED12 mutation frequency reported herein may represent an 355 
underestimate of the actual number in the Hispanic population, since our sequencing 356 
analysis was restricted to exon 2, whereas exon 1 is also a target for pathogenic MED12 357 
mutations. Nonetheless, mutations in exon 1 account for ~6% of all those recorded in UFs, 358 
and therefore, any underestimate in the actual MED12 mutation frequency reported 359 
herein is likely to be small (23). Altogether, our tumor analyses provide further 360 
confirmation that MED12 driver mutations are common in UFs from women of diverse 361 
racial and ethnic backgrounds, including Hispanic women.  362 
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Within Mediator, MED12 binds directly to CycC, and this interaction is essential for 363 
MED12-mediated activation of CDK8/19. In this study, we mapped the minimal CycC-364 
binding and CDK8 activation domain on MED12 to amino acids 15-80 that completely 365 
encompass MED12 residues (amino acids 26-68) impacted by UF-linked mutations. 366 
Accordingly, the fact that no UF-linked mutations in MED12 lie outside of its 367 
biochemically defined CycC-CDK8 binding and activation domain argues strongly that 368 
Mediator kinase disruption is the principal biochemical defect arising from these 369 
oncogenic mutations. Herein, we validate this prediction in the pathologically relevant 370 
setting of patient-derived UFs. Thus, comparative analyses of Mediator complexes 371 
recovered from WT and mutant MED12-expressing UFs confirmed unequivocally that UF-372 
linked MED12 mutations disrupt Mediator kinase activity, implicating CDK8/19 in UF 373 
pathogenesis.  374 
The mechanistic basis by which Mediator kinase disruption contributes to UF 375 
formation remains to be established, but likely involves dysregulation of CDK8/19-376 
dependent gene expression programs. Consistent with this notion, we previously found by 377 
comparative gene expression profiling that MED12 WT and MED12 mutant UFs stratify 378 
according to their unique gene expression signatures (23,36), suggesting that MED12 mutant 379 
UFs constitute a distinct molecular subtype with a unique path to tumorigenesis. 380 
Furthermore, we note that Mediator kinase activity is known to regulate multiple 381 
signaling pathways linked to UF development, including the WNT/b-catenin, TGF-b, and 382 
estrogen receptor a (ERa) pathways, among others. In this regard, canonical WNT/b-383 
catenin signaling is implicated in UF growth, and recent studies suggest its involvement as a 384 
paracrine effector of estrogen signaling in UF stem cells (37). Furthermore, MED12-mutant 385 
tumors support elevated levels of WNT4 expression (17). Notably, the Mediator kinase module 386 
has been linked directly to control of WNT/b-catenin signaling, first by our finding that MED12 387 
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is a direct transducer of WNT-activated b-catenin, and subsequently by the discovery that 388 
CDK8 promotes oncogenic WNT signaling by virtue of its dual role as a β-catenin coactivator 389 
and a suppressor of E2F1, a negative regulator of b-catenin (27). TGF-b is a key regulator of 390 
UF fibrosis and growth. TGF-b signaling stimulates smooth muscle cell proliferation and 391 
promotes fibroid formation through stimulation of ECM-promoting genes and inhibition of 392 
matrix-resorbing genes (38). Significantly, MED12 is an established suppressor of oncogenic 393 
TGF-b signaling, and CDK8 has been shown to instigate a phosphorylation-dependent SMAD 394 
action turnover switch that regulates the amplitude and duration of TGFb-driven and SMAD-395 
dependent transcriptional responses (39). Finally, ERa, as a principal mediator of estrogen 396 
action, is an important promoter of UF growth, and CDK8 was recently identified as a potent 397 
downstream mediator of transcriptional and mitogenic signaling by ERa (40). Thus, disruption 398 
of Mediator kinase activity as a consequence of pathogenic mutations in MED12 could 399 
trigger dysregulated signal-dependent gene expression programs that contribute to UF 400 
formation. Nonetheless, CDK8 has been shown to phosphorylate a plethora of additional 401 
substrates with established or prospective roles in gene regulation, including DNA-binding 402 
transcription factors, components of the Pol II transcriptional apparatus, and diverse 403 
signaling molecules, including those involved in DNA damage response and repair (28). 404 
Further studies will be required to identify key substrates of Mediator kinases most 405 
relevant to UF pathogenesis. 406 
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Figure Legends 541 
 542 
Figure 1. Representative sequence chromatograms reveal MED12 codon 44 mutation 543 
status in patient-derived UFs and myometrium. Examples of genomic DNA (A, C, E) and 544 
cDNA (B, D, F) sequencing traces in codon 44 mutated UF samples and a wild-type UF 545 
sample (G) is shown along with a genomic DNA sequencing trace from a myometrium 546 
sample (H). Codon 44 is highlighted by the horizontal bars below the traces. Mutated 547 
bases are indicated by arrows. 548 
 549 
Figure 2. Identification of the minimal CycC-CDK8 binding and activation domain on 550 
MED12. (A) Schematic diagram of GST-MED12 (1-100) C-terminal and N-terminal 551 
truncation derivatives used in binding and activation assays. (B and C) Glutathione-552 
sepharose-immobilized GST or GST-MED12 (1-00) and its C-terminal (B) and N-terminal 553 
(C) truncation derivatives as indicated were incubated with whole cell lysates from insect 554 
cells co-expressing baculovirus-produced human CycC-CDK8. Bound proteins were eluted with 555 
Laemmli sample buffer and processed by western blot (WB) using the indicated antibodies or 556 
incubated with [γ-32P]-ATP and purified GST-CTD prior to resolution by SDS-PAGE and 557 
phosphorimager analyses (CTD-32P). Coomassie blue stained gels show the levels of GST-MED12 558 
derivatives (marked by bullets) and GST-CTD substrate (CTD) used in binding and kinase 559 
reactions, respectively. Molecular weight markers (kD) are indicated. Input (IN) corresponds 560 
to 10% of insect cell lysate used in IP reactions. 32P-GST-CTD levels were quantified and 561 
expressed relative to the level obtained in the presence of GST-MED12 (1-100), which was 562 
assigned a value of 100%. Data represent the average +/- SEM of 3 independent experiments. 563 
Asterisks denote statistically significant differences versus MED12-GST (1-100)-stimulated 564 
kinase activity (Student’s t test, *** p < 0.001: * p < 0.01). (D) Schematic diagram indicating 565 
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the experimentally defined minimal CycC-CDK8 binding and activation (bind/act) domain 566 
relative to MED12 exon sequences. This region (amino acids 15-80) circumscribes all 567 
recorded UF linked mutations in MED12. 568 
 569 
Figure 3. Mediator kinase activity is selectively disrupted in MED12-mutant UF tumors. Whole 570 
tissue lysates from patient-matched (A) or unmatched (B and C) UF tumor sets, including one 571 
MED12 WT and one MED12 mutant UF tumor each, were subjected to IP with MED12-specific 572 
antibodies or control IgG as indicated. Patient-matched samples in (A) correspond to UF 573 
tumor 104Fa (MED12 WT) and UF tumor 104Fb (MED12 G44R). Unmatched samples in (B) 574 
correspond to UF tumor 104Fa (MED12 WT) and UF tumor 102Fa (MED12 G44D). Unmatched 575 
samples in (C) correspond to UF tumor 114Fb (MED12 WT) and UF tumor 128Fa (MED12 G44V). 576 
MED12-specific IPs were resolved by SDS-10% PAGE and processed by WB analysis using the 577 
indicated Mediator subunit-specific antibodies (top panels) or subjected to in vitro kinase 578 
assay prior to resolution by SDS-PAGE and phosphorimager analyses (bottom panels). Input 579 
corresponds to 10% of tissue lysates used in IPs. Molecular weight markers (kD) are indicated. 580 
32P-GST-CTD levels were quantified and expressed relative those obtained in kinase reactions 581 
with WT MED12/Mediator IPs which were assigned a value of 100%. 582 
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Table 2
# of Patients
Total
Hispanic
# of Fibroids sequenced# of Myometrium sequenced # of MED12 Mut Mutation (%)
76
57
219
170
121
92
55.3%
54.1%
28
21
Other 19 7 49 29 59.2%
Table 2. MED12 mutation frequency among UF patients
Table 3
Type Location Nucleotide change Predicted protein change Number of mutations out 121 (%)
Missense Exon 2 c.131G>C p.G44A 5 (4.1)
Exon 2 c.130G>T p.G44C 8 (6.6)
Exon 2 c.131G>A p.G44D 40 (33.1)
Exon 2 c.130G>C p.G44R 8 (6.6)
Exon 2 c.130G>A p.G44S 25 (20.7)
Exon 2 c.107T>G p.L36R 10 (8.3)
Exon 2 c.204A>G p.K68E 1 (0.8)
Deletion Exon 2
Exon 2
Exon 2
Exon 2
Exon 2
Exon 2
c.117_131del15
c.100-9_132del42insGG
c.100-2_138del41
c.124_153del30
c.139_153del15
c.100_144del45
p.L39P_G44del
p.D34_G44del
p.D34_N46del
p.N47_V51del
p.K42_V51del
p.D34_Q48del
1 (0.8)
1 (0.8)
1 (0.8)
1 (0.8)
1 (0.8)
1 (0.8)
Exon 2 c.131G>T p.G44V 18 (14.9)
Table 3. MED12 mutation type in UF tumors
Individual Ethnicity Age Solitary/Multiple fibroids Uterine Fibroids Diameter (cm)
7 Hispanic 37 Multiple 7b 8 cm
10 Hispanic 41 Multiple 10Fa 4 cm
10Fb 3.5 cm
10Fc 2.5 cm
11 Hispanic 56 Multiple 11Fa 4 cm
11Fb 5 cm
11Fc NR
11Fd 4 cm
12 Hispanic 43 Single 12F 8 cm
MRKH Hispanic 29 Single MRKH-M NR
MRKH-F 8 cm
14 Hispanic 44 Single 14Fa < 1 cm
15 Hispanic 47 Multiple 15Fb 2 cm
15Fc 4 cm
16 Hispanic 43 Multiple 16M NR
16Fa 2 cm
16Fb 2 cm
17 Hispanic 39 Single 17M NR
17Fa 10 cm
18 Hispanic 37 Multiple 18M NR
18Fa 12 cm
18Fb 3 cm
19 Hispanic 32 Multiple 19Fc 3 cm
19Fd 1 cm
20 Hispanic 46 Multiple 20Fa 2.5 cm
20Fc 1.5 cm
20Fe 1 cm
20Fh 1 cm
21 Hispanic 45 Multiple 21Fa 5 cm
21Fb 2 cm
21Fc 4 cm
21Fd 3 cm
Table S1. Summary of clinicopathological data for Hispanic UF
patients
Supplemental Table S1
22 Hispanic 40 Multiple 22Fa 10 cm
22Fb 1 cm
22Fc 3 cm
22Fd 2 cm
22Fe 2 cm
22Ff 2 cm
22Fg 2 cm
23 Hispanic 40 Multiple 23M 3 cm
23Fa 15 cm
23Fc 3 cm
24 Hispanic 39 Multiple 24Fa NR
24Fb NR
25 Hispanic 41 Multiple 25M 3 cm
25Fa 2.5 cm
25Fb 0.5 cm
25Fc 1 cm
26 Hispanic 42 Multiple 26M NR
26Fa 15 cm
26Fb 2 cm
27 Hispanic 50 Multiple 27M NR
27Fa NR
27Fb NR
28 Hispanic 51 Multiple 28M NR
28Fa 5 cm
28Fb 5 cm
29 Hispanic 40 Multiple 29M 3 cm
29Fa 3 cm
29Fb 3 cm
29Fc 3 cm
32 Hispanic 39 Multiple 32Fa 10 cm
32Fb 10 cm
32Fc 8 cm
32Fd 4 cm
34 Hispanic 35 Multiple 34Fb NR
34Fc NR
34Fe NR
35 Hispanic 33 Single 35M NR
35Fa 4 cm
36 Hispanic 39 Single 36M NR
36Fa NR
37 Hispanic 45 Multiple 37M NR
37Fa NR
37Fb NR
37Fc NR
37Fd NR
39 Hispanic 37 Multiple 39M NR
39Fa 5 cm
39Fb 1 cm
40 Hispanic 48 Multiple 40M NR
40Fb NR
40Fc NR
40Fd NR
41 Hispanic 48 Multiple 41M NR
41Fa NR
41Fb NR
41Fc NR
42 Hispanic 51 Multiple 42M NR
42Fa NR
42Fb NR
42Fc NR
43 Hispanic 49 Single 43Fa NR
44 Hispanic 49 Multiple 44M NR
44Fa NR
44Fb NR
44Fc NR
47 Hispanic 41 Multiple 47M NR
47Fa NR
47Fb NR
47Fc NR
50 Hispanic 61 Single 50Fa 3 cm
51 Hispanic 39 Single 51Fa NR
86 Hispanic 37 Multiple 86M NR
86Fa 5 cm
86Fb 4 cm
86Fc 2 cm
87 Hispanic 41 Multiple 87Fc 0.5 cm
87Fd 0.5 cm
87Fe 2 cm
87Ff 0.3 cm
88 Hispanic 49 Multiple 88Fa 3 cm
91 Hispanic 28 Multiple 91Fa 5 cm
91Fb 6 cm
91Fc 5 cm
93 Hispanic 47 Multiple 93M NR
93Fa 4 cm
93Fb 3 cm
94 Hispanic 44 Multiple 94Fa 2 cm
94Fb 1.5 cm
94Fc 2.5 cm
95 Hispanic 41 Single 95Fa 2 cm
97 Hispanic 43 Single 97Fa 4 cm
99 Hispanic NR Multiple 99Fa 2 cm
99Fb 2 cm
99Fc 1.5 cm
102 Hispanic 34 Single 102Fa 15 cm
104 Hispanic 42 Multiple 104Fa 6 cm
104Fb 3 cm
104Fc 3 cm
104Fd 2 cm
104Fe 2 cm
104Ff 1.5 cm
104Fg 1 cm
104Fh 1 cm
104Fi 1 cm
104Fj 0.7 cm
104Fl 1.5 cm
104Fn 0.8 cm
104Fo 0.5 cm
104Fr 1 cm
104Fs 0.5 cm
104Fu 0.3 cm
104Fw 0.3 cm
104Fx 0.3 cm
107 Hispanic 42 Multiple 107Fa 4.5 cm
110 Hispanic 42 Multiple 110Fa 1.8 cm
110Fb 1 cm
110Fc 0.5 cm
114 Hispanic 38 Multiple 114Fa 2 cm
114Fb 9 cm
115 Hispanic 47 Multiple 115Fb 1.5 cm
115Fc 1.5 cm
115Fd 1 cm
118 Hispanic 48 Multiple 118Fa 11 cm
118Fc 3.5 cm
118Fd 3.8 cm
118Fe 2.0 cm
119 Hispanic 35 Multiple 119Fa 8 cm
119Fc 2 cm
120 Hispanic 41 Single 120Fa 0.5 cm
121 Hispanic 60 Multiple 121Fa 4 cm
121Fb 2.5 cm
121Fc 0.3 cm
121Fd 0.5 cm
122 Hispanic 45 Multiple 122Fc 0.3 cm
122Fd 0.3 cm
125 Hispanic 48 Multiple 125Fa 3.5 cm
125Fb 1.2 cm
125Fd 0.7 cm
125Fe 1.5 cm
125Ff 1 cm
125Fg 0.8 cm
125Fi 0.5 cm
125Fj 0.3 cm
126 Hispanic 45 Multiple 126Fa 0.8 cm
126Fb 0.5 cm
126Fc 0.7 cm
126Fe 0.6 cm
126Ff 0.6 cm
126Fg 0.3 cm
126Fh 0.7 cm
M: Myometrium 
F: Uterine Fibroid
NR: Not Reported 
Individual Ethnicity Age Solitary/Multiple Fibroids Uterine Fibroids Diameter (cm)
6 Caucasian 33 Single 6a 4 cm
9 African American 50 Multiple 9Fc 3 cm
13 African American 57 Multiple 13Fa NR
13Fb NR
30 Caucasian 36 Multiple 30M NR
30Fa 8 cm
30Fb 5 cm
30Fc 3 cm
38 Caucasian 47 Multiple 38M 3 cm
38Fa 5 cm
38Fb 5 cm
38Fc 3 cm
45 Chinese 34 Single 45Fa 12 cm
46 African American 30 Multiple 46Fa 3 cm
46Fb 3 cm
46Fc 2 cm
46Fd 2 cm
46Fe 1.5 cm
48 Caucasian 43 Multiple 48Fa 1 cm
48Fb 1 cm
49 African American 32 Single 49Fa 4 cm
52 African American 39 Multiple 52Fa NR
52Fb NR
53 African American 54 Multiple 53M 4 cm
53Fb 7 cm
53Fc 5 cm
54 Caucasian 36 Multiple 54M 1 cm
54Fa 10 cm
54Fc 2 cm
55 Caucasian 44 Multiple 55M NR
55Fa 6 cm
55Fb 2 cm
Table S2. Summary of clinicopathological data for non-Hispanic UF
patients
Supplemental Table S2
55Fc 1 cm
65 African American 50 65M NR
85 African American 37 Multiple 85Fa NR
85Fb NR
85Fc NR
89 Caucasian 44 Multiple 89Fa 18 cm
89Fb 5 cm
89Fc 2 cm
90 Caucasian 37 Multiple 90M NR
90Fb 2 cm
90Fc 1 cm
90Fd 0.5 cm
90Fe 0.5 cm
90Fi 1 cm
90Fl 1 cm
90Fn 0.4 cm
90Fp 0.2 cm
96 African American 39 Multiple 96Fa 2.5 cm
96Fb 2.5 cm
96Fc 2 cm
96Fd 1.5 cm
96Fe 0.5 cm
96Fg 0.5 cm
98 Iranian 47 Single 98Fa 1.5 cm
M: Myometrium 
F: Uterine Fibroid
NR: Not Reported 
Individual Myo/Fib MED12 Status Individual Myo/Fib MED12 Status 
7 7b wt 19 19Fd wt
10 10Fa c.130G>T, p.G44C 20 20Fa c.131G>A, p.G44D
10 10Fb c.107T>G, p.L36R 20 20Fc c.131G>A, p.G44D
10 10Fc c.130G>A, p.G44S 20 20Fe c.130G>C, p.G44R
10 10Fd c.131G>A, p.G44D 20 20Fh c.131G>A, p.G44D
10 10Fe c.130G>A, p.G44S 21 21Fa wt
10 10Ff c.130G>A, p.G44S 21 21Fb wt
10 10Fg c.131G>A, p.G44D 21 21Fc wt
10 10Fh c.107T>G, p.L36R 21 21Fd wt
10 10Fi c.131G>A, p.G44D 22 22Fa c.107T>G, p.L36R
10 10Fj c.130G>A, p.G44S 22 22Fb c.131G>C, p.G44A
10 10Fk c.131G>A, p.G44D 22 22Fc c.130G>T, p.G44C
10 10Fl c.107T>G, p.L36R 22 22Fd c.131G>T, p.G44V
11 11Fa c.131G>T, p.G44V 22 22Fe c.131G>T, p.G44V
11 11Fb c.131G>A, p.G44D 22 22Ff c.100-9_132del42insGG,
p.D34_G44del
11 11Fc c.204A>G, p.K68E 22 22Fg c.130G>C, p.G44R
11 11Fd c.130G>A, p.G44S 23 23M wt
12 12F c.130G>A, p.G44S 23 23Fa wt
MRKH MRKH-M wt 23 23Fc wt
MRKH MRKH-F c.131G>A, p.G44D 24 24Fa wt
14 14Fa c.131G>A, p.G44D 24 24Fb wt
15 15Fb c.117_131del15, p.L39P_G44del 25 25M wt
15 15Fc c.130G>A, p.G44S 25 25Fa wt
16 16M wt 25 25Fb wt
16 16Fa wt 25 25Fc wt
16 16Fb wt 26 26M wt
17 17M wt 26 26Fa wt
17 17Fa wt 26 26Fb wt
18 18M wt 27 27M wt
18 18Fa wt 27 27Fa c.131G>T, p.G44V
18 18Fb wt 27 27Fb c.131G>A, p.G44D
19 19Fc c.131G>A, p.G44D 28 28M wt
Table S3. Summary of MED12 mutation status in Hispanic UF patients
Supplemental Table S3
Individual Myo/Fib MED12 Status Individual Myo/Fib MED12 Status 
28 28Fa wt 44 44Fa wt
28 28Fb c.100-2_138del41,
p.D34_N46del
44 44Fb wt
29 29M wt 44 44Fc wt
29 29Fa c.131G>A, p.G44D 47 47M wt
29 29Fb wt 47 47Fa wt
29 29Fc c.131G>A, p.G44D 47 47Fb wt
32 32Fa wt 47 47Fc c.130G>A, p.G44S
32 32Fb wt 50 50Fa wt
32 32Fc wt 51 51Fa c.131G>A, p.G44D
32 32Fd wt 86 86M wt
34 34Fb c.139_153del15, p.N47_V51del 86 86Fa wt
34 34Fc wt 86 86Fb wt
34 34Fe wt 86 86Fc wt
35 35M wt 87 87Fc wt
35 35Fa wt 87 87Fd c.131G>A, p.G44D
36 36M wt 87 87Fe wt
36 36Fa c.131G>A, p.G44D 87 87Ff c.131G>T, p.G44V
37 37M wt 88 88Fa c.131G>A, p.G44D
37 37Fa wt 91 91Fa wt
37 37Fb wt 91 91Fb wt
37 37Fc wt 91 91Fc wt
37 37Fd wt 93 93M wt
39 39M wt 93 93Fa c.130G>T, p.G44C
39 39Fa wt 93 93Fb wt
39 39Fb wt 94 94Fa wt
40 40M wt 94 94Fb wt
40 40Fb wt 94 94Fc wt
40 40Fc wt 95 95Fa wt
40 40Fd wt 97 97Fa wt
41 41M wt 99 99Fa c.131G>T, p.G44V
41 41Fa wt 99 99Fb c.131G>T, p.G44V
41 41Fb wt 99 99Fc c.130G>A, p.G44S
41 41Fc c.131G>C, p.G44A 102 102Fa c.131G>A, p.G44D
42 42M wt 104 104Fa wt
42 42Fa wt 104 104Fb c.130G>C, p.G44R
42 42Fb wt 104 104Fc c.130G>C, p.G44R
42 42Fc c.131G>A, p.G44D 104 104Fd wt
43 43Fa c.130G>A, p.G44S 104 104Fe c.131G>C, p.G44A
44 44M wt 104 104Ff c.130G>C, p.G44R
Individual Myo/Fib MED12 Status Individual Myo/Fib MED12 Status 
104 104Fg wt 119 119Fc wt
104 104Fh c.130G>A, p.G44S 120 120Fa wt
104 104Fi c.130G>A, p.G44S 121 121Fa c.130G>A, p.G44S
104 104Fj c.130G>A, p.G44S 121 121Fb c.131G>A, p.G44D
104 104Fl c.130G>T, p.G44C 121 121Fc c.131G>A, p.G44D
104 104Fn c.107T>G, p.L36R 121 121Fd c.130G>A, p.G44S
104 104Fo c.130G>T, p.G44C 122 122Fc wt
104 104Fr c.130G>A, p.G44S 122 122Fd c.130G>T, p.G44C
104 104Fs c.130G>A, p.G44S 125 125Fa c.131G>T, p.G44V
104 104Fu c.130G>T, p.G44C 125 125Fb c.131G>T, p.G44V
104 104Fw c.130G>C, p.G44R 125 125Fd c.131G>A, p.G44D
104 104Fx c.107T>G, p.L36R 125 125Fe c.130G>A, p.G44S
107 107Fa c.107T>G, p.L36R 125 125Ff c.131G>A, p.G44D
110 110Fa wt 125 125Fg c.131G>A, p.G44D
110 110Fb c.131G>T, p.G44V 125 125Fi wt
110 110Fc wt 125 125Fj wt
114 114Fa wt 126 126Fa c.130G>A, p.G44S
114 114Fb wt 126 126Fb c.130G>A, p.G44S
115 115Fb wt 126 126Fc c.131G>A, p.G44D
115 115Fc c.107T>G, p.L36R 126 126Fe c.131G>T, p.G44V
115 115Fd c.131G>A, p.G44D 126 126Ff wt
118 118Fa wt 126 126Fg c.131G>A, p.G44D
118 118Fc c.131G>A, p.G44D 126 126Fh c.131G>A, p.G44D
118 118Fd c.130G>A, p.G44S
118 118Fe c.131G>A, p.G44D
119 119Fa wt
Myo: Myometrium 
Fib: Uterine Fibroid
wt: wild type 
Individual Myo/Fib MED12 Status Individual Myo/Fib MED12 Status 
6 6a wt 55 55M wt
9 9Fc wt 55 55Fa wt
13 13Fa c.131G>C, p.G44A 55 55Fb wt
13 13Fb c.131G>T, p.G44V 55 55Fc c.131G>T, p.G44V
30 30M wt 65 65M wt
30 30Fa c.130G>T, p.G44C 85 85Fa c.131G>A, p.G44D
30 30Fb c.107T>G, p.L36R 85 85Fb c.131G>A, p.G44D
30 30Fc c.131G>A, p.G44D 85 85Fc wt
38 38M wt 89 89Fa wt
38 38Fa wt 89 89Fb c.131G>A, p.G44D
38 38Fb wt 89 89Fc wt
38 38Fc wt 90 90M wt
45 45Fa wt 90 90Fb c.131G>A, p.G44D
46 46Fa wt 90 90Fc c.131G>T, p.G44V
46 46Fb c.130G>C, p.G44R 90 90Fd c.130G>A, p.G44S
46 46Fc wt 90 90Fe c.131G>T, p.G44V
46 46Fd wt 90 90Fi c.131G>A, p.G44D
46 46Fe c.130G>C, p.G44R 90 90Fl c.131G>A, p.G44D
48 48Fa wt 90 90Fn c.131G>C, p.G44A
48 48Fb wt 90 90Fp c.131G>A, p.G44D
49 49Fa wt 96 96Fa c.130G>A, p.G44S
52 52Fa wt 96 96Fb c.107T>G, p.L36R
52 52Fb wt 96 96Fc c.130G>A, p.G44S
53 53M wt 96 96Fd wt
53 53Fb c.124_153del30, p.K42_V51del 96 96Fe c.100_144del45, p.D34_Q48del
53 53Fc c.131G>T, p.G44V 96 96Fg c.131G>T, p.G44V
54 54M wt 98 98Fa c.131G>A, p.G44D
54 54Fa c.131G>T, p.G44V
54 54Fc c.130G>A, p.G44S
Myo: Myometrium 
Fib: Uterine Fibroid
wt: wild type 
Table S4. Summary of MED12 mutation status in non-Hispanic UF patients
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